Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

JAMA Dermatol · 2025 · PMC12019677 · PMID 40266575

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Improvement in itch and hives was rapid, as demonstrated by the nominally significant and clinically meaningful change in UAS7 from baseline observed at week 4 compared with placebo (LS mean difference, −6.60 [95% CI, −11.22 to −1.97]).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.